BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 21351498)

  • 21. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma.
    Huang SK; Mayhew E; Gilani S; Lasic DD; Martin FJ; Papahadjopoulos D
    Cancer Res; 1992 Dec; 52(24):6774-81. PubMed ID: 1458465
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma membrane targeting by short chain sphingolipids inserted in liposomes improves anti-tumor activity of mitoxantrone in an orthotopic breast carcinoma xenograft model.
    Cordeiro Pedrosa LR; van Tellingen O; Soullié T; Seynhaeve AL; Eggermont AM; Ten Hagen TL; Verheij M; Koning GA
    Eur J Pharm Biopharm; 2015 Aug; 94():207-19. PubMed ID: 25982691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice.
    Moo KS; Radhakrishnan S; Teoh M; Narayanan P; Bukhari NI; Segarra I
    Yao Xue Xue Bao; 2010 Jul; 45(7):901-8. PubMed ID: 20931790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tissue distribution evaluation of stealth pH-sensitive liposomal cisplatin versus free cisplatin in Ehrlich tumor-bearing mice.
    Júnior AD; Mota LG; Nunan EA; Wainstein AJ; Wainstein AP; Leal AS; Cardoso VN; De Oliveira MC
    Life Sci; 2007 Jan; 80(7):659-64. PubMed ID: 17141809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I clinical trial of pegylated liposomal mitoxantrone plm60-s: pharmacokinetics, toxicity and preliminary efficacy.
    Yang J; Shi Y; Li C; Gui L; Zhao X; Liu P; Han X; Song Y; Li N; Du P; Zhang S
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):637-46. PubMed ID: 25034977
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics, pharmacodynamics and metabolism of a novel anticancer agent for prostate cancer.
    Yang J; Ahn S; Wu Z; Hwang DJ; Miller DD; Dalton JT
    Int J Oncol; 2012 Jul; 41(1):337-44. PubMed ID: 22576690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity.
    Adlakha-Hutcheon G; Bally MB; Shew CR; Madden TD
    Nat Biotechnol; 1999 Aug; 17(8):775-9. PubMed ID: 10429242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide.
    Chen X; Wang X; Wang Y; Yang L; Hu J; Xiao W; Fu A; Cai L; Li X; Ye X; Liu Y; Wu W; Shao X; Mao Y; Wei Y; Chen L
    J Control Release; 2010 Jul; 145(1):17-25. PubMed ID: 20307599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics, safety, and efficacy of a liposome encapsulated thymidylate synthase inhibitor, OSI-7904L [(S)-2-[5-[(1,2-dihydro-3-methyl-1-oxobenzo[f]quinazolin-9-yl)methyl]amino-1-oxo-2-isoindolynl]-glutaric acid] in mice.
    Desjardins J; Emerson DL; Colagiovanni DB; Abbott E; Brown EN; Drolet DW
    J Pharmacol Exp Ther; 2004 Jun; 309(3):894-902. PubMed ID: 14982966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor activity and pharmacokinetic properties of ARS-interacting multi-functional protein 1 (AIMP1/p43).
    Han JM; Myung H; Kim S
    Cancer Lett; 2010 Jan; 287(2):157-64. PubMed ID: 19573982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study.
    Marra M; Salzano G; Leonetti C; Porru M; Franco R; Zappavigna S; Liguori G; Botti G; Chieffi P; Lamberti M; Vitale G; Abbruzzese A; La Rotonda MI; De Rosa G; Caraglia M
    Biotechnol Adv; 2012; 30(1):302-9. PubMed ID: 21741464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone.
    Lim HJ; Masin D; Madden TD; Bally MB
    J Pharmacol Exp Ther; 1997 Apr; 281(1):566-73. PubMed ID: 9103545
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues.
    Patel KJ; Trédan O; Tannock IF
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):127-38. PubMed ID: 23680920
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liposomal imatinib-mitoxantrone combination: formulation development and therapeutic evaluation in an animal model of prostate cancer.
    Pinto AC; Moreira JN; Simões S
    Prostate; 2011 Jan; 71(1):81-90. PubMed ID: 20607721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts.
    Colbern GT; Dykes DJ; Engbers C; Musterer R; Hiller A; Pegg E; Saville R; Weng S; Luzzio M; Uster P; Amantea M; Working PK
    Clin Cancer Res; 1998 Dec; 4(12):3077-82. PubMed ID: 9865923
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma.
    Stover TC; Sharma A; Robertson GP; Kester M
    Clin Cancer Res; 2005 May; 11(9):3465-74. PubMed ID: 15867249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
    Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
    Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In-vitro cytotoxicity, in-vivo biodistribution and anti-tumour effect of PEGylated liposomal topotecan.
    Hao YL; Deng YJ; Chen Y; Wang KZ; Hao AJ; Zhang Y
    J Pharm Pharmacol; 2005 Oct; 57(10):1279-87. PubMed ID: 16259756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liposomal pravastatin inhibits tumor growth by targeting cancer-related inflammation.
    Coimbra M; Banciu M; Fens MH; de Smet L; Cabaj M; Metselaar JM; Storm G; Schiffelers RM
    J Control Release; 2010 Dec; 148(3):303-10. PubMed ID: 20869410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.